Scandinavian ChemoTech Q4 2024: Initial take - Redeye

Redeye gives its initial comments on the Q4 2024 report from Scandinavian ChemoTech, which was mostly in line with our estimates for operating performance. Sales came in at cSEK2.0m, against our forecasted cSEK2.4m. Although slightly below what we had foreseen, it is still the company's strongest quarter to date, with c50% of the top line stated to come from recurring revenue in the form of treatment kits. We expect to make some slight revisions to our estimates building on the previously communicated information about the separation of business segments and the financials presented in the report.

Länk till analysen i sin helhet: https://www.redeye.se/research/1086036/scandinavian-chemotech-q4-2024-initial-take?utm_source=finwire&utm_medium=RSS